Thomas McGlashan
Dr. Thomas McGlashan (born 1942) is an American professor of psychiatry at Yale University, well known for his academic contributions to the study of schizophrenia and other mental illnesses.
Professional career
He obtained his medical qualification from the University of Pennsylvania in 1967, and was a staff member in
In the 1990s he embarked upon work focused on interventions early in the course of schizophrenia, and became an early advocate and researcher in early detection and intervention for psychosis,[3] including being a key participant in the Norway early detection studies (TIPS) [4] and PRIME studies on early treatment of those at risk of schizophrenia [5] The study reported that the drug Olanzapine had a "trend significant" effect in preventing conversion to psychosis and that further, larger studies are warranted.[6]
Professor Thomas McGlashan is the current recipient of the Richard Wyatt Award,
Books
- The documentation of clinical psychotropic drug trials by Thomas H McGlashan - 1973)
- The Borderline: Current Empirical Research by Thomas H. McGlashan (1985)
Co-authored:
- Early Intervention in Psychotic Disorders (Nato Science Series: D Behavioural and Social Sciences, Volume 91) (NATO Science Series D: (closed)) by Tandy Miller, Sarnoff A. Mednick, Thomas H. McGlashan, and Jan Libiger (Hardcover - Nov 2001)
- Schizophrenia: Treatment Process and Outcome by Thomas H. McGlashan and Christopher J. Keats (1989)
- A Developmental Model of Borderline Personality Disorder: Understanding Variations in Course and Outcome by Patricia Hoffman Judd and Thomas H. McGlashan (2002)
References
- ^ Carey, Benedict (2006-05-23). "A Career That Has Mirrored Psychiatry's Twisting Path". The New York Times. Retrieved 2008-01-18.
- PMID 6428370.
- PMID 8782281.
- PMID 16055803.
- S2CID 1118339.
- PMID 16648318.
- ^ "The Richard J. Wyatt Award". Archived from the original on 2009-10-30. Retrieved 2010-06-23.